Deltagen Research Laboratories
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Deltagen Research Laboratories
Cerep Moves Beyond Services
Can slow and steady win the drug-discovery race? France's Cerep prepares to find out, as it pushes past its fee-for-service start.
CombiChem Squeezes Through a Narrow Exit Door
CombiChem's acquisition by DuPont deal is, somewhat paradoxically, yet further proof of the difficulty that early-stage biotechs will have in finding Big Pharma buyers. Unless discovery biotechs are offering something specifically appropriate to a particular drug firm, even moderately valued acquisitions are unlikely exit opportunities.
Biotech: Making Money the Old-Fashioned Way
At the January 1999 Hambrecht & Quist meeting, investors were hearing a new message from biotechs: the Millennium-ization of the industry. Platform companies are promising to leverage their technologies much more aggressively for many more customers. They'll identify their assets, sell them, and sell them again.
Combinatorial Power
Riccardo Pigliucci, former CEO of Life Sciences International PLC and past president and COO of Perkin Elmer Corp. thinks he has found a model that will serve the small companies' needs to build value, keep up with technological innovation and create large enough operations to make Big pharma feel comfortable in dealing with them. Discovery Partners International is a sort of holding company for drug discovery tool companies. It has made its first investments in combinatorial chemistry company Irori and chemical library provider ChemRx.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice